You are here: Industry Insights > Alzheimer’s disease

News List

Pharmaceutical News of the Week (July. 13th-July. 17th) | PharmaSources.com - Updates on R&D PharmaSources/Caicai
July 22, 2020
With the third week of July coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions, and miscellany that happened during July 13-17, including 30 pieces.
Eli Lilly announces mid-stage trial success for donanemab in Alzheimer’s pharmatimes
January 14, 2021
Donanemab, an investigational antibody developed by Eli Lilly, has demonstrated positive results in a phase IIa trial in patients with early-stage Alzheimer’s disease (AD).
Noncommunicable diseases are leading cause of death and disability worldwide, says WHO europeanpharmaceuticalreview
December 11, 2020
Alzheimer’s and diabetes enter the top ten global causes of death for the first time, while HIV/AIDS and tuberculosis deaths fall, according to the WHO’s 2019 Global Health Estimates.
Neuraly gets FDA clearance of INDA to initiate phase 2b trial of NLY01 in Alzheimer’s Disease pharmaceutical-business-review
November 06, 2020
Neuraly announced it has received clearance of an investigational new drug application (IND) to initiate a Phase 2B trial of NLY01 in patients with Alzheimer’s disease.
EMA accepts marketing application for Biogen, Eisai’s Alzheimer’s therapy pharmaceutical-technology
November 04, 2020
Biogen and Eisai have announced that the European Medicines Agency (EMA) accepted to review the marketing authorisation application (MAA) for aducanumab, an investigational antibody therapy for Alzheimer’s disease.
Re-purposed drugs could reverse blood vessel damage in diabetes expresspharma
June 30, 2020
In a breakthrough, scientists have discovered a key mechanism that triggers changes in the blood vessels, which can eventually lead to cardiovascular disease.
US FDA approves first drug to image Tau Pathology in Alzheimer’s Disease related cases expresspharma
June 01, 2020
Tauvid is a radioactive diagnostic agent for adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease.
China’s First Innovative Drug for Alzheimer’s Disease: GV-971 Marketed at RMB895 PharmaSources/Dishui Sinan
January 06, 2020
The innovative drug for Alzheimer’s disease (AD)-GV-971 (sodium oligomannurarate) has been officially marketed in China, which is priced at RMB895/box and has attracted much attention of the pharmaceutical practitioners.
CTD Holdings Files Supporting Data for Alzheimer’s Disease Patent americanpharmaceuticalreview
August 14, 2019
CTD Holdings has filed supporting data for its patent application titled “Methods for Treating Alzheimer’s Disease.” The original patent application was filed October 29, 2018 for the use of hydroxypropyl beta cyclodextrins in the treatment of Alzheimer’s
Data sharing uncovers five new risk genes for Alzheimer’s disease biospectrumasia
March 05, 2019
Analysis of genetic data from more than 94,000 individuals has revealed five new risk genes for Alzheimer’s disease, and confirmed 20 known others.

Previous page 1 2 3 Next page